J0742 HCPCS Level II code: Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
J0742 is the HCPCS code for “Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J0742Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
Short description: Inj imip 4 cilas 4 releb 2mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J0742 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jul 1, 2020
Where J0742 sits
- 1J codesDrugs administered other than orally
- 2Active code J0742Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J0742 mean?
J0742 is the HCPCS code for “Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J0742?
CMS lists J0742’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0742
All J codesJ0736Injection, clindamycin phosphate, 300 mgJ0737Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mgJ0738Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)J0739Injection, cabotegravir, 1mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)J0740Injection, cidofovir, 375 mgJ0741Injection, cabotegravir and rilpivirine, 2mg/3mgJ0743Injection, cilastatin sodium; imipenem, per 250 mgJ0744Injection, ciprofloxacin for intravenous infusion, 200 mgJ0745Injection, codeine phosphate, per 30 mgJ0750Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)J0751Emtricitabine 200mg and tenofovir alafenamide 25mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)J0752Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)